On August 29, 2025 Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, reported change of date and time of management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8-10, 2025 in New York City, to Monday, September 8, at 5:00 PM Eastern Time (Press release, Pasithea Therapeutics, AUG 29, 2025, View Source [SID1234655585]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pasithea CEO, Dr. Tiago Reis Marques, will deliver a live company presentation, and management will be available for one-on-one meetings throughout the event.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference
Date: September 8, 2025
Time: 5:00 PM ET
Location: Lotte New York Palace Hotel
Webcast: Register